ey0020.5-2 | Clinical Guidance and Studies | ESPEYB20
N Brix , A Gaml-Sorensen , A Ernst , LH Arendt , LL Harrits Lunddorf , G Toft , SS Tottenborg , KK Haervig , BB Hoyer , KS Hougaard , JPE Bonde , CH Ramlau-Hansen
ey0021.6-5 | Clinical and Molecular Insights into SF1 Deficiency | ESPEYB21
C Kouri , G Sommer , I Martinez de Lapiscina , RN Elzenaty , LJW Tack , M Cools , SF Ahmed , CE; SF1next study group Fluck
ey0021.6-12 | Gender Incongruence - Hormone Treatment Continuation | ESPEYB21
BS Cavve , X Bickendorf , J Ball , LA Saunders , CS Thomas , P Strauss , G Chaplyn , L Marion , A Siafarikas , U Ganti , A Wiggins , A Lin , JK Moore
ey0021.14-12 | Risk and Outcome | ESPEYB21
Wang Zheng , Van Faassen Martijn , Groen Henk , Cantineau Astrid E.P. , Van Oers Anne , Van der Veen Anna , Hawley James M. , Keevil Brian G. , Kema Ido P. , Hoek Annemieke
ey0021.15-4 | New Treatments | ESPEYB21
S Osataphan , M Vamvini , ED Rosen , L Pei , N Erlikh , G Singh , P Dhorajiya , JA Parker , JM Dreyfuss , A Rattani , ME. Patti
ey0018.1-2 | Development/Ontogeny | ESPEYB18
F Ruf-Zamojski , Z Zhang , M Zamojski , GR Smith , N Mendelev , H Liu , G Nudelman , M Moriwaki , H Pincas , RG Castanon , VD Nair , N Seenarine , MAS Amper , X Zhou , L Ongaro , C Toufaily , G Schang , JR Nery , A Bartlett , A Aldridge , N Jain , GV Childs , OG Troyanskaya , JR Ecker , JL Turgeon , CK Welt , DJ Bernard , SC Sealfon
ey0018.4-6 | Growth Hormone Therapy: Safety | ESPEYB18
L Savendahl , R Cooke , A Tidblad , D Beckers , G Butler , S Cianfarani , P Clayton , J Coste , ACS Hokken-Koelega , W Kiess , CE Kuehni , K Albertsson-Wikland , A Deodati , E Ecosse , R Gausche , C Giacomozzi , D Konrad , F Landier , R Pfaeffle , G Sommer , M Thomas , S Tollerfield , GRJ Zandwijken , JC Carel , AJ Swerdlow
ey0018.8-8 | Clinical Trials – New Treatments | ESPEYB18
K Clement , E van den Akker , J Argente , A Bahm , WK Chung , H Connors , K De Waele , IS Farooqi , J Gonneau-Lejeune , G Gordon , K Kohlsdorf , C Poitou , L Puder , J Swain , M Stewart , G Yuan , M Wabitsch , P; Setmelanotide POMC and LEPR Phase 3 Trial Investigators Kuhnen
ey0019.6-4 | Co-morbidities associated with DSD | ESPEYB19
LJW Tack , der Straaten S van , S Riedl , A Springer , PM Holterhus , NC Hornig , Z Kolesinska , M Niedziela , F Baronio , A Balsamo , SE Hannema , A Nordenstrom , S Poyrazoglu , FF Darendeliler , R Grinspon , R Rey , F Aljuraibah , J Bryce , F Ahmed , R Tadokoro-Cuccaro , I Hughes , G Guaragna-Filho , AT Maciel-Guerra , G Guerra-Junior , M Cools
ey0019.6-5 | Basic and Genetic Research of DSD | ESPEYB19
D Cicek , N Warr , G Yesil , Eker H Kocak , F Bas , S Poyrazoglu , F Darendeliler , G Direk , N Hatipoglu , M Eltan , Abali Z Yavas , Tosun B Gurpinar , SB Kaygusuz , Menevse T Seven , D Helvacioglu , S Turan , A Bereket , R Reeves , M Simon , M Mackenzie , L Teboul , A Greenfield , T Guran